LBPEC-01 is under clinical development by Locus Biosciences and currently in Phase II for Escherichia coli Infections. According to GlobalData, Phase II drugs for Escherichia coli Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the LBPEC-01 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LBPEC-01 overview

LBPEC-01 is under development for the treatment of Escherichia coli (E.coli) Infections in patients with urinary tract infections and asymptomatic bacteriuria. The drug candidate is a CRISPR-engineered bacteriophage (crPhage) developed based on CRISPR-Cas3 technology. It is administered through intravenous route.

Locus Biosciences overview

Locus Biosciences (Locus) is a biotechnology company that develops and commercializes antimicrobial therapeutics for antibiotic-resistant bacterial infections and microbiome-related disorders. The company offers a CRISPR Cas3-engineered phage (crPhage) platform that is used as a treatment for urinary tract infections caused by Escherichia coli. Its crPhage products kill the DNA of target bacteria cells, including antibiotic-resistant superbugs, while leaving non-targeted species unharmed. The company works in collaboration with academic, research and pharmaceutical companies to develop its product portfolio. Locus is headquartered in Morrisville, North Carolina, the US.

For a complete picture of LBPEC-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.